



## BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences

February 26, 2020

NEW HAVEN, Conn., Feb. 26, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at two upcoming healthcare investor conferences.

### Conference Presentation Details:

**Event:** Cowen and Co. 40th Annual Health Care Conference  
**Date/Time:** Wednesday, March 4, 2020 at 10:00 a.m. Eastern Time  
**Location:** Boston, MA

**Event:** Barclays Global Healthcare Conference  
**Date/Time:** Tuesday, March 10, 2020 at 3:50 p.m. Eastern Time  
**Location:** Miami, FL

Live webcasts from the Cowen and Barclays conference presentations and any accompanying presentation materials that will be discussed will be accessible through the Investors section of the Company's website at [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com). Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for at least 30 days.

### About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com).

### Contact Information:

BioXcel Therapeutics, Inc.  
[www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com)

Investor Relations:  
John Graziano  
[jgraziano@troutgroup.com](mailto:jgraziano@troutgroup.com)  
1.646.378.2942

Media:  
Julia Deutsch  
[jdeutsch@troutgroup.com](mailto:jdeutsch@troutgroup.com)  
1.646.378.2967

Source: BioXcel Therapeutics